ProShare Advisors
OVID icon

ProShare Advisors’s Ovid Therapeutics OVID Stock Holding History

ProShare Advisors’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$51.6K Buy
20,737
+688
+3% +$1.8K ﹤0.01% 1767
2026
Q2 		$53.9K Buy
+20,049
New +$51.7K ﹤0.01% 1837
2025
Q2 		– Sell
-12,754
Closed -$3.98K – 2156
2025
Q1 		$3.98K Sell
12,754
-3,830
-23% -$2.36K ﹤0.01% 2078
2024
Q4 		$15.5K Buy
16,584
+1,263
+8% +$1.41K ﹤0.01% 2258
2024
Q3 		$18.1K Buy
15,321
+2,956
+24% +$3.09K ﹤0.01% 2049
2024
Q2 		$9.5K Sell
12,365
-3,301
-21% -$9.19K ﹤0.01% 1838
2024
Q1 		$47.8K Buy
15,666
+1,281
+9% +$4.29K ﹤0.01% 1908
2023
Q4 		$46.3K Buy
+14,385
New +$49.2K ﹤0.01% 1870
2021
Q4 		– Sell
-14,511
Closed -$49K – 2345
2021
Q3 		$49K Buy
14,511
+2,328
+19% +$8.49K ﹤0.01% 1966
2021
Q2 		$48K Sell
12,183
-9,306
-43% -$36.7K ﹤0.01% 2361
2021
Q1 		$86K Buy
21,489
+1,156
+6% +$3.84K ﹤0.01% 2182
2020
Q4 		$47K Buy
+20,333
New +$94.8K ﹤0.01% 2050

Other funds holding OVID

Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return
Abel Hall LLC
Abel Hall LLC Baton Rouge, Louisiana $556M AUM 43.18% 1-Year Est. Return
Total Clarity Wealth Management
Total Clarity Wealth Management St. Charles, Illinois $518M AUM 17.26% 1-Year Est. Return
Benin Management Corp
Benin Management Corp Wilton, Connecticut $517M AUM 21.33% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Empirical Wealth Management
Empirical Wealth Management Seattle, Washington $7.38B AUM 22.9% 1-Year Est. Return
Aaron Wealth Advisors
Aaron Wealth Advisors Chicago, Illinois $2.04B AUM 32.69% 1-Year Est. Return
Sterling Capital Management
Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

ProShare Advisors's OVID Position: Q3 2026 in Review

ProShare Advisors increased its Ovid Therapeutics (OVID) stake by 3.4% in Q3 2026, buying an estimated $1.8K and bringing the position to 20,737 shares worth $51.6K. The position accounts for ﹤0.01% of the portfolio, ranked #1767.

ProShare Advisors first reported a position in OVID in Q4 2020 and has held it in 12 quarters since. The position peaked at $86K in Q1 2021. 17 funds tracked by Wall St. Rank hold OVID as of Q3 2026.

  • ProShare Advisors held 20,737 shares of Ovid Therapeutics worth $51.6K as of Q3 2026.
  • ProShare Advisors bought 688 Ovid Therapeutics shares in Q3 2026, an estimated $1.8K.
  • Ovid Therapeutics made up ﹤0.01% of ProShare Advisors's portfolio in Q3 2026, its #1767 holding.
  • ProShare Advisors first reported a position in Ovid Therapeutics in Q4 2020 and has held it in 12 quarters since.
  • ProShare Advisors's Ovid Therapeutics position peaked at $86K in Q1 2021.
  • 17 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q3 2026.

Based on ProShare Advisors's 13F filing for Q3 2026, filed 29 Oct 2026.